

“

**This condition has caused me to limit my life and my world to what feels like only a fraction of my true self.**

”

“

**I can't tell you how many times I've wanted to give up because I am tired of being tired and living my life this way, or better yet, not living my life. It is a helpless feeling.**

”

Quotes from individuals living with sleep-wake disorders, *Illuminate Hypersomnia* “Voice of the Patient” Report, 2024

This brochure makes reference to potential therapies that are the subject of clinical studies and which have not been approved by the FDA or any other regulatory agency.

#### References:


- Mahoney CE, et al. **The neurobiological basis of narcolepsy.** *Nat Rev Neurosci.* 2019;20: 83–93.
- Kornum et al, **Narcolepsy.** *Nat Rev Dis Primers.* 3:16100 (2017)
- Black SW, et al. **Challenges in the development of therapeutics for narcolepsy.** *Prog Neurobiol.* 2017;152: 89-113.
- Dauvilliers Y, et al. **Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.** *N Engl J Med.* 2023 Jul 27;389(4):309-321. doi: 10.1056
- Mignot E, et al. **Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.** *Sleep.* 2023 Sep 8;46(9):zsad049. doi: 10.1093/sleep/zsad049.
- Evans R, et al **Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.** *Proc Natl Acad Sci U S A.* 2022 Aug 30;119(35):e2207531119. doi: 10.1073/pnas.2207531119.
- CDER, 2013. **The Voice of the Patient: Narcolepsy,** Ed. Silver Spring, MD, U.S. FDA, pp. 1–25. [Accessed 02 January 2024]. <http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM402907.pdf>
- **Illuminate Hypersomnia “Voice of the Patient” Report:** U.S. FDA. <https://sleepconsortium.org/illuminatehypersomnia/>
- **The Drug Development Process,** U.S. FDA <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process>

sleep\_wake\_disorders\_brochure\_v1.0\_10Oct 2024\_ENG

# New Possibilities for Sleep-Wake Disorders

# Orexin: a potential pathway to target for sleep-wake disorders

Orexin (also called hypocretin) is a signaling molecule in the brain that controls wakefulness.



Orexin is a chemical messenger called a neuropeptide which helps brain cells communicate with each other.




During the day, orexin levels increase to help us stay awake.



During the night, orexin levels decrease, allowing us to sleep.

Orexin acts like the 'conductor of the orchestra' for wakefulness in the brain.



Like a conductor who unifies the music from an orchestra, orexin is believed to help coordinate brain activities to produce wakefulness.

## Why target orexin?

Orexin agonists are designed to activate orexin receptors, like a key opening a lock, to produce signals that keep us awake.



## What's happening next?

- Orexin agonists are being investigated in clinical studies for the potential treatment of certain sleep-wake disorders.
- Once all necessary studies are completed, regulatory authorities will review the results and determine if the investigational new drug is safe and effective for its intended use.